|
Endometrial Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
The expression of HOXA10 was detected by Immunofluorescence staining in endometrial cancer tissues and adjacent normal tissues.
|
29618950 |
2018 |
|
Endometrial Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
The expression of lncRNA H19 and HOXA10 was high in endometrial carcinoma and miR-612 was lowly expressed.
|
30070313 |
2018 |
|
Endometrial Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Expression of HOXA10 and p21 gene decreased in endometrial cancer, and the expression level of HOXA10 was correlated with cancer grade.
|
24943991 |
2014 |
|
Endometrial Carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
The expression of HOXA10 was deregulated in endometrial carcinomas and up-regulated by sex hormones.
|
21670700 |
2011 |
|
Endometrial Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
The expression of HOXA10 was deregulated in endometrial carcinomas and up-regulated by sex hormones.
|
21670700 |
2011 |
|
Endometrial Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
These findings reveal a novel role for HOXA10 deregulation in the progression of endometrial carcinoma by promoting epithelial-mesenchymal transition.
|
16424022 |
2006 |
|
Liver carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Thus, the function of HoxA10 is similar to the action of interferon (IFN) in terms of inhibition of HBV infection; however, the mechanism of HoxA10-mediated repression of HBV replication is different from the mechanism underlying IFN-induced inhibition of HBV infection.<b>IMPORTANCE</b> Two billion people have been infected with HBV worldwide; about 240 million infected patients developed chronic hepatitis B (CHB), and 650,000 die each year from liver cirrhosis (LC) or hepatocellular carcinoma (HCC).
|
30674631 |
2019 |
|
Liver carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
RNA interference-mediated knockdown of HOXA10 inhibited HCC cell proliferation both in vitro and in vivo.
|
31440094 |
2019 |
|
Liver carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Liver carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Bioinformatic method was applied to predict the binding of miR-218 on HoxA10, and western blotting was used to examine the modulatory effect of miR-218 AND HoxA10 on PTEN/AKT/PI3K pathway in HCC.
|
25120782 |
2014 |
|
Adenocarcinoma
|
0.330 |
Biomarker
|
group |
CTD_human |
Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro.
|
21670700 |
2011 |
|
Adenocarcinoma
|
0.330 |
Biomarker
|
group |
BEFREE |
Furthermore, methylation of PENK, BCL2, RUNX3, DLEC1, MT1G, GRIN2B, CDH13, CCND2, and HOXA10 was significantly more frequent in invasive ADC than AAH or AIS.
|
21494759 |
2011 |
|
Adenocarcinoma
|
0.330 |
AlteredExpression
|
group |
BEFREE |
Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro.
|
21670700 |
2011 |
|
Adenocarcinoma
|
0.330 |
AlteredExpression
|
group |
BEFREE |
HOXA10 expression is elevated in high nuclear grade stage I and II endometrial adenocarcinomas.
|
15627890 |
2005 |
|
Endometrial Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro.
|
21670700 |
2011 |
|
Endometrial Neoplasms
|
0.310 |
Biomarker
|
group |
LHGDN |
Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial-mesenchymal transition.
|
16424022 |
2006 |
|
Adenocarcinoma, Basal Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro.
|
21670700 |
2011 |
|
Adenocarcinoma, Oxyphilic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro.
|
21670700 |
2011 |
|
Carcinoma, Cribriform
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro.
|
21670700 |
2011 |
|
Carcinoma, Granular Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro.
|
21670700 |
2011 |
|
Adenocarcinoma, Tubular
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro.
|
21670700 |
2011 |
|
Female Urogenital Diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Development of the mammalian female reproductive tract.
|
16002989 |
2005 |
|
Endometriosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since it is well known that aberrant expression of HOXA10 is involved in pathogenesis of the endometrium, our data emphasized the epigenetic role of this gene aberration related to clinical pathophysiology of endometriosis.
|
29592776 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study provides human and mouse evidence to suggest tumor suppressive roles for HOXA10 in the context of prostate cancer.
|
30614022 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Upregulated HOXA10 promoted GC cell proliferation with reduced apoptosis in vitro and accelerated GC tumor growth in vivo.
|
31364281 |
2019 |